drug

Eicosapentaenoic acid (omega-3 fatty acid)

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of Pittsburgh Medical Center
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
NCT00167310Phase 2Completed

KOLs & investigators

1
Jeffrey K Yao, Ph.D., FACB

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of Pittsburgh Medical Center
company
trial
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
PHASE2
trial
indication
Schizophrenia
indication
Major Depression
indication
Coronary Artery Disease
indication
Bipolar Disorder
indication
KOL
Jeffrey K Yao, Ph.D., FACB
KOL score —
person